Hemorheologic factors probably play a role in the pathogenesis and prognosis of
retinal vein occlusion. Accordingly, we designed a prospective, randomized, double-masked study to evaluate the effect of
troxerutin, a rheologic
drug, on
retinal vein occlusion. Fifty-three patients were included, 27 with
central retinal vein occlusion and 26 with
branch retinal vein occlusion. They were randomly assigned for treatment with either
troxerutin or a placebo. All subjects were similar in age, gender, associated diseases, hemorheologic values, and clinical severity of the
retinal vein occlusion. At the end of follow-up, members of the
troxerutin-treated group, as compared with the placebo group, showed significant improvement in visual acuity (P = .03), macular threshold (P = .01),
retinal circulation times (P = .04), and
macular edema (P = .05). Furthermore, they had diminished progression of
ischemia (P = .05) and decreased red blood cell aggregability (P = .006) when compared with the controls. These encouraging preliminary results obtained with a rheologic treatment attest to the pathogenic role of blood viscosity in
retinal vein occlusion and suggest that a large-scale randomized study should be conducted.